FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308203719> ?p ?o ?g. }

• W4308203719 endingPage "1839" @default.
• W4308203719 startingPage "1839" @default.
• W4308203719 abstract "Interstitial pneumonia is a severe complication induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Several treatments have been proposed alone or, more often, in combination, depending, also, on the presence of other organ disfunction. The most frequently related, well-described, and associated phenomenon is pan-lymphopenia with circulating, high levels of cytokines. We report, here, on two patients with COVID-19 and lymphoproliferative disorders treated with Tocilizumab (a humanized monoclonal antibody against the interleukin-6 receptor) and followed by an [18F]FDG PET/CT to early evaluate the therapy's efficacy.One patient with angioimmunoblastic T-lymphoma (A), one with Hodgkin lymphoma (A), and both with positive RT-PCR for SARS-CoV-2 and with similar clinical findings of interstitial pneumonia at the CT scan, were imaged by [18F]FDG PET/CT before and 14 days after a single dose of Tocilizumab.In both patients, the basal [18F]FDG PET/CT showed a diffused lung parenchyma uptake, corresponding to the hyperdense areas at the CT scan. After 2 weeks of a Tocilizumab infusion, patient B had an improvement of symptoms, with normalization of the [18F]FDG uptake. By contrast, patient A, who was still symptomatic, showed a persisting and abnormal distribution of [18F]FDG. Interestingly, both patients showed a low bone marrow uptake of [18F]FDG at the diagnosis and after 15 days, while the spleen uptake was low only in lymphopenic patient A; both are indirect signs of an immune deficiency.In conclusion, in these two patients, interstitial pneumonia was efficiently treated with Tocilizumab, as demonstrated by the [18F]FDG PET/CT. Our results confirm that interleukin-6 (IL6) has a role in the COVID-19 disease and that anti-cytokine treatment can also be performed in patients with lymphoproliferative disorders." @default.
• W4308203719 created "2022-11-09" @default.
• W4308203719 creator A5000987788 @default.
• W4308203719 creator A5002806059 @default.
• W4308203719 creator A5010369186 @default.
• W4308203719 creator A5020540245 @default.
• W4308203719 creator A5020613095 @default.
• W4308203719 creator A5023003831 @default.
• W4308203719 creator A5042687061 @default.
• W4308203719 creator A5070129134 @default.
• W4308203719 creator A5070155938 @default.
• W4308203719 creator A5072114845 @default.
• W4308203719 creator A5088840950 @default.
• W4308203719 creator A5090996707 @default.
• W4308203719 date "2022-11-04" @default.
• W4308203719 modified "2023-10-14" @default.
• W4308203719 title "[18F]FDG PET/CT in Patients Affected by SARS-CoV-2 and Lymphoproliferative Disorders and Treated with Tocilizumab" @default.
• W4308203719 cites W2001380210 @default.
• W4308203719 cites W2120801007 @default.
• W4308203719 cites W3006385584 @default.
• W4308203719 cites W3011740120 @default.
• W4308203719 cites W3012721127 @default.
• W4308203719 cites W3019771519 @default.
• W4308203719 cites W3022494590 @default.
• W4308203719 cites W3024244771 @default.
• W4308203719 cites W3029715706 @default.
• W4308203719 cites W3032935481 @default.
• W4308203719 cites W3033493606 @default.
• W4308203719 cites W3033986164 @default.
• W4308203719 cites W3082612767 @default.
• W4308203719 cites W3093701219 @default.
• W4308203719 cites W3110844195 @default.
• W4308203719 cites W3118283464 @default.
• W4308203719 cites W3119076954 @default.
• W4308203719 cites W3163235237 @default.
• W4308203719 cites W3181620419 @default.
• W4308203719 cites W4206449744 @default.
• W4308203719 cites W4225094282 @default.
• W4308203719 cites W4286253383 @default.
• W4308203719 cites W4296993868 @default.
• W4308203719 cites W4306910712 @default.
• W4308203719 doi "https://doi.org/10.3390/jpm12111839" @default.
• W4308203719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36579547" @default.
• W4308203719 hasPublicationYear "2022" @default.
• W4308203719 type Work @default.
• W4308203719 citedByCount "1" @default.
• W4308203719 crossrefType "journal-article" @default.
• W4308203719 hasAuthorship W4308203719A5000987788 @default.
• W4308203719 hasAuthorship W4308203719A5002806059 @default.
• W4308203719 hasAuthorship W4308203719A5010369186 @default.
• W4308203719 hasAuthorship W4308203719A5020540245 @default.
• W4308203719 hasAuthorship W4308203719A5020613095 @default.
• W4308203719 hasAuthorship W4308203719A5023003831 @default.
• W4308203719 hasAuthorship W4308203719A5042687061 @default.
• W4308203719 hasAuthorship W4308203719A5070129134 @default.
• W4308203719 hasAuthorship W4308203719A5070155938 @default.
• W4308203719 hasAuthorship W4308203719A5072114845 @default.
• W4308203719 hasAuthorship W4308203719A5088840950 @default.
• W4308203719 hasAuthorship W4308203719A5090996707 @default.
• W4308203719 hasBestOaLocation W43082037191 @default.
• W4308203719 hasConcept C126322002 @default.
• W4308203719 hasConcept C126838900 @default.
• W4308203719 hasConcept C127077266 @default.
• W4308203719 hasConcept C142724271 @default.
• W4308203719 hasConcept C2775842073 @default.
• W4308203719 hasConcept C2777178219 @default.
• W4308203719 hasConcept C2777575956 @default.
• W4308203719 hasConcept C2777714996 @default.
• W4308203719 hasConcept C2777914695 @default.
• W4308203719 hasConcept C2779338263 @default.
• W4308203719 hasConcept C2780007613 @default.
• W4308203719 hasConcept C71924100 @default.
• W4308203719 hasConcept C90924648 @default.
• W4308203719 hasConceptScore W4308203719C126322002 @default.
• W4308203719 hasConceptScore W4308203719C126838900 @default.
• W4308203719 hasConceptScore W4308203719C127077266 @default.
• W4308203719 hasConceptScore W4308203719C142724271 @default.
• W4308203719 hasConceptScore W4308203719C2775842073 @default.
• W4308203719 hasConceptScore W4308203719C2777178219 @default.
• W4308203719 hasConceptScore W4308203719C2777575956 @default.
• W4308203719 hasConceptScore W4308203719C2777714996 @default.
• W4308203719 hasConceptScore W4308203719C2777914695 @default.
• W4308203719 hasConceptScore W4308203719C2779338263 @default.
• W4308203719 hasConceptScore W4308203719C2780007613 @default.
• W4308203719 hasConceptScore W4308203719C71924100 @default.
• W4308203719 hasConceptScore W4308203719C90924648 @default.
• W4308203719 hasIssue "11" @default.
• W4308203719 hasLocation W43082037191 @default.
• W4308203719 hasLocation W43082037192 @default.
• W4308203719 hasLocation W43082037193 @default.
• W4308203719 hasLocation W43082037194 @default.
• W4308203719 hasOpenAccess W4308203719 @default.
• W4308203719 hasPrimaryLocation W43082037191 @default.
• W4308203719 hasRelatedWork W1495619015 @default.
• W4308203719 hasRelatedWork W2171422777 @default.
• W4308203719 hasRelatedWork W2348836856 @default.
• W4308203719 hasRelatedWork W2369117338 @default.
• W4308203719 hasRelatedWork W2416406993 @default.

• next